David Planchard/oncostream.com
Apr 16, 2025, 16:51
David Planchard: Targeting DLL3 – A new weapon in lung neuroendocrine tumors?
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared LinkedIn post about recent paper he and his colleague authored:
“Things are finally king in NEMs lung…to be continued!
Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors? | JTO Clinical and Research Reports.”
Authors: Mariona Riudavets, David Planchard
Read more about “Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates” on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 09:10
Jun 2, 2025, 09:06
Jun 2, 2025, 08:58
Jun 2, 2025, 08:57
Jun 2, 2025, 08:50